Please use this identifier to cite or link to this item: https://ahro.austin.org.au/austinjspui/handle/1/28738
Full metadata record
DC FieldValueLanguage
dc.contributor.authorDalton, Emily J-
dc.contributor.authorChurilov, Leonid-
dc.contributor.authorLannin, Natasha A-
dc.contributor.authorCorbett, Dale-
dc.contributor.authorCampbell, Bruce C V-
dc.contributor.authorHayward, Kathryn S-
dc.date2021-06-04-
dc.date.accessioned2022-02-01T04:45:16Z-
dc.date.available2022-02-01T04:45:16Z-
dc.date.issued2021-08-
dc.identifier.citationNeurorehabilitation and neural repair 2021; 35(8): 663-679en
dc.identifier.urihttps://ahro.austin.org.au/austinjspui/handle/1/28738-
dc.description.abstractDespite an increase in the amount of published stroke recovery research, interventions have failed to markedly affect the trajectory of recovery poststroke. We argue that early-phase research to systematically investigate dose is an important contributor to advance the science underpinning stroke recovery. In this article, we aim to (a) define the problem of insufficient use of a systematic approach to early-phase, multidimensional dose articulation research and (b) propose a solution that applies this approach to design a multidimensional phase I trial to identify the maximum tolerated dose (MTD). We put forward a design template as a decision support tool to increase knowledge of how to develop a phase I dose-ranging trial for nonpharmaceutical stroke recovery interventions. This solution has the potential to advance the development of efficacious stroke recovery interventions, which include activity-based rehabilitation interventions.en
dc.language.isoeng-
dc.subjectclinical trialsen
dc.subjectdoseen
dc.subjectmaximum tolerable doseen
dc.subjectphase Ien
dc.subjectstroke rehabilitationen
dc.subjectupper limben
dc.titleMultidimensional Phase I Dose Ranging Trials for Stroke Recovery Interventions: Key Challenges and How to Address Them.en
dc.typeJournal Articleen
dc.identifier.journaltitleNeurorehabilitation and neural repairen
dc.identifier.affiliationThe Florey Institute of Neuroscience and Mental Health..en
dc.identifier.affiliationMedicine (University of Melbourne)..en
dc.identifier.affiliationMonash University, Melbourne, VIC, Australia..en
dc.identifier.affiliationAlfred Health, Melbourne, Australia..en
dc.identifier.affiliationUniversity of Ottawa, Ottawa, Canada..en
dc.identifier.affiliationMelbourne Brain Centre, Royal Melbourne Hospital, Parkville, VIC, Australia..en
dc.identifier.pubmedurihttps://pubmed.ncbi.nlm.nih.gov/34085851/en
dc.identifier.doi10.1177/15459683211019362en
dc.type.contentTexten
dc.identifier.orcid0000-0003-3920-8530en
dc.identifier.orcid0000-0003-0217-4576en
dc.identifier.orcid0000-0002-9807-6606en
dc.identifier.orcid0000-0001-5240-3264en
dc.identifier.pubmedid34085851-
local.name.researcherChurilov, Leonid
item.openairecristypehttp://purl.org/coar/resource_type/c_18cf-
item.cerifentitytypePublications-
item.fulltextNo Fulltext-
item.grantfulltextnone-
item.languageiso639-1en-
item.openairetypeJournal Article-
crisitem.author.deptMedicine (University of Melbourne)-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
crisitem.author.deptThe Florey Institute of Neuroscience and Mental Health-
Appears in Collections:Journal articles
Show simple item record

Page view(s)

22
checked on Mar 28, 2024

Google ScholarTM

Check


Items in AHRO are protected by copyright, with all rights reserved, unless otherwise indicated.